Luigi Cerbone, Alessia Garau, Tiziana Borra, Paola Barbieri, Rebecca Parisi, Claudia Leporati, Marco Ghiglione, Federica Grosso
{"title":"Spontaneous remission of Merkel cell carcinoma presenting with tertiary lymphoid structures in an immunocompetent patient.","authors":"Luigi Cerbone, Alessia Garau, Tiziana Borra, Paola Barbieri, Rebecca Parisi, Claudia Leporati, Marco Ghiglione, Federica Grosso","doi":"10.4081/dr.2026.10799","DOIUrl":null,"url":null,"abstract":"<p><p>Dear Editor, Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer predominantly affecting elderly males, with a median age at diagnosis of 76 years. Its pathogenesis is linked to three main risk factors: UV exposure, Merkel cell polyomavirus (MCPyV) infection, and immunosuppression. Standard management of localized disease (stage I/II) consists of wide local excision with sentinel lymph node biopsy (SLNB), followed by adjuvant radiotherapy according to disease stage. Despite optimal multimodal treatment, prognosis remains poor, with more than 50% of patients progressing to metastatic disease and a median overall survival of approximately 20 months with first-line avelumab. [...].</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/dr.2026.10799","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Dear Editor, Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer predominantly affecting elderly males, with a median age at diagnosis of 76 years. Its pathogenesis is linked to three main risk factors: UV exposure, Merkel cell polyomavirus (MCPyV) infection, and immunosuppression. Standard management of localized disease (stage I/II) consists of wide local excision with sentinel lymph node biopsy (SLNB), followed by adjuvant radiotherapy according to disease stage. Despite optimal multimodal treatment, prognosis remains poor, with more than 50% of patients progressing to metastatic disease and a median overall survival of approximately 20 months with first-line avelumab. [...].